IMG-007 Market Summary

Key Factors Driving IMG-007 Growth

1. Differentiated OX40 Mechanism with Potential Safety Advantages

IMG-007 targets the OX40 receptor, a key regulator of activated T cells involved in chronic inflammatory diseases. Unlike some earlier OX40-targeting antibodies, IMG-007 has been engineered with a silenced antibody-dependent cellular cytotoxicity (ADCC) function, allowing it to block OX40/OX40L signaling without depleting T cells. This design may reduce safety concerns associated with immune-cell depletion while maintaining efficacy. Company management has highlighted this non-depleting approach as a key differentiator within the OX40 class.

2. Strong Early Efficacy in Atopic Dermatitis

In a Phase IIa study in moderate-to-severe atopic dermatitis, IMG-007 demonstrated substantial clinical activity. After a 4-week treatment regimen, patients achieved a 77% mean reduction in Eczema Area and Severity Index (EASI) and an EASI-75 response rate of 54% at Week 16. Importantly, efficacy appeared durable, with sustained suppression of inflammatory biomarkers observed for up to 24 weeks. These results compare favorably with efficacy reported for several other emerging OX40-pathway therapies.

3. Extended Half-Life Supports Convenient Infrequent Dosing

One of IMG-007's most commercially attractive features is its extended half-life of approximately 35 days. Based on pharmacokinetic findings, the company believes the drug may support maintenance dosing intervals as long as every 24 weeks in certain settings. Less frequent dosing could improve patient adherence, enhance physician preference, and provide a competitive advantage against biologics requiring monthly or biweekly administration.

4. Advancement into a Large Phase IIb Program

In July 2025, ImageneBio initiated the global ADAPTIVE Phase IIb trial evaluating multiple dose regimens of IMG-007 in moderate-to-severe atopic dermatitis. The trial initially targeted approximately 220 patients and has since been expanded to roughly 400 patients under an amended protocol designed to optimize exposure, dosing intervals, and durability of response. Top-line data are expected in Q4 2026, representing a major value-inflection point for the program.

5. Expansion Opportunity in Alopecia Areata

Beyond atopic dermatitis, IMG-007 has shown encouraging activity in alopecia areata, a rapidly growing dermatology market. In a Phase IIa study, patients receiving the higher-dose regimen demonstrated sustained improvement in Severity of Alopecia Tool (SALT) scores through Week 36, with mean SALT reductions of approximately 22–30% depending on baseline disease severity. The durability of response observed months after treatment cessation supports further development in this indication and broadens the drug's commercial opportunity.

6. Favorable Safety Profile Supports Long-Term Use

Safety remains a critical differentiator in chronic dermatologic diseases. Across clinical studies involving more than 150 participants, IMG-007 has demonstrated a favorable tolerability profile. ImageneBio reported no treatment-related serious adverse events, no cases of administration-associated pyrexia or chills, and no observed serious infections or malignancies attributable to treatment. Such findings may support long-term use if confirmed in larger studies.

IMG-007 Recent Developments

In April 2026, ImageneBio, Inc. announced a private placement led by Coastlands Capital, aiming to raise approximately USD 30 million to advance its lead drug, IMG-007, in the treatment of alopecia areata and moderate-to-severe atopic dermatitis. This receptor-targeting, non-depleting OX40 antagonist is currently undergoing clinical trials, including a Phase IIb study in atopic dermatitis. Imagene's CEO, Kristin Yarema, expressed enthusiasm for the collaboration with institutional investors, highlighting IMG-007’s potential to modify disease outcomes. The placement involves pre-funded warrants to acquire common stock at a specified price, with customary resale registration rights provided to investors. The securities have not been registered under the Securities Act, limiting their resale unless properly registered.

“IMG-007 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of IMG-007 for potential indication like Atopic dermatitis and Alopecia areata in the 7MM. A detailed picture of IMG-007’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the IMG-007 for potential indications. The IMG-007 market report provides insights about IMG-007’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IMG-007 performance, future market assessments inclusive of the IMG-007 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IMG-007 sales forecasts, along with factors driving its market.

IMG-007 Drug Summary

IMG-007 is an investigational, long-acting, non-depleting humanized monoclonal antibody developed by Inmagene Biopharmaceuticals that targets OX40 (CD134), a co-stimulatory receptor expressed on activated T cells involved in the pathogenesis of multiple autoimmune and inflammatory diseases. By selectively blocking OX40 signaling, IMG-007 inhibits T-cell activation, proliferation, and survival, thereby reducing downstream inflammatory responses while avoiding broad immune cell depletion. Engineered with an extended half-life to support less frequent dosing, the drug is administered via subcutaneous injection and is being evaluated for indications including Atopic Dermatitis and Alopecia Areata. Early clinical studies have demonstrated favorable pharmacokinetics, target engagement, and a generally well-tolerated safety profile, supporting its potential as a differentiated immune-modulating therapy capable of providing durable disease control through upstream regulation of pathogenic T-cell responses. The report provides IMG-007’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the IMG-007 Market Report

The report provides insights into:

• A comprehensive product overview including the IMG-007 MoA, description, dosage and administration, research and development activities in potential indication like Atopic dermatitis and Alopecia areata.
• Elaborated details on IMG-007 regulatory milestones and other development activities have been provided in IMG-007 market report.
• The report also highlights IMG-007‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The IMG-007 market report also covers the patents information, generic entry and impact on cost cut.
• The IMG-007 market report contains current and forecasted IMG-007 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IMG-007 market report also features the SWOT analysis with analyst views for IMG-007 in potential indications.

Methodology

The IMG-007 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMG-007 Analytical Perspective by DelveInsight

• In-depth IMG-007 Market Assessment

This IMG-007 sales market forecast report provides a detailed market assessment of IMG-007 for potential indication like Atopic dermatitis and Alopecia areata in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IMG-007 sales data uptil 2034.

• IMG-007 Clinical Assessment

The IMG-007 market report provides the clinical trials information of IMG-007 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

IMG-007 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IMG-007 Market Potential & Revenue Forecast

• Projected market size for the IMG-007 and its key indications
• Estimated IMG-007 sales potential (IMG-007 peak sales forecasts)
• IMG-007 Pricing strategies and reimbursement landscape

IMG-007 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• IMG-007 Market positioning compared to existing treatments
• IMG-007 Strengths & weaknesses relative to competitors

IMG-007 Regulatory & Commercial Milestones

• IMG-007 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

IMG-007 Clinical Differentiation

• IMG-007 Efficacy & safety advantages over existing drugs
• IMG-007 Unique selling points

IMG-007 Market Report Highlights

• In the coming years, the IMG-007 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IMG-007 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMG-007’s dominance.
• Other emerging products for Atopic dermatitis and Alopecia areata are expected to give tough market competition to IMG-007 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMG-007 in potential indications.
• Analyse IMG-007 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IMG-007 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IMG-007 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of IMG-007? How strong is IMG-007’s clinical and commercial performance?
• What is IMG-007’s clinical trial status in each individual indications such as Atopic dermatitis and Alopecia areata and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMG-007 Manufacturers?
• What are the key designations that have been granted to IMG-007 for potential indications? How are they going to impact IMG-007’s penetration in various geographies?
• What is the current and forecasted IMG-007 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IMG-007 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IMG-007 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is IMG-007? What is the duration of therapy and what are the geographical variations in cost per patient?